Gennex Laboratories Ltd. (GENNE) Share Price Rises 8.13% as Micro Cap Stock Enters Top Gainers

Gennex Laboratories Ltd. rose to Rs 11.7, up 8.13% today, taking its market capitalisation to Rs 262.87 crore and placing it among notable micro cap gainers.

Gennex Laboratories Ltd. Share Price moved up to Rs 11.7 on 17 August 2026, a gain of 8.13% over the previous close of Rs 10.82, lifting the company’s market capitalisation to Rs 262.87 crore. That makes Gennex Laboratories Ltd. Share Price Today one of the more visible movers in the micro cap basket, and it explains why the stock is featuring in Top Gainers Today screens and Stocks in News lists.

The verified data confirms the price rise, the turnover and the volume participation, but it does not establish a company-specific catalyst behind today’s move. Even without a stated trigger, the stock’s move matters because it has cleared the workflow’s price-rise event filter for its market-cap category, placing this Healthcare name from the Pharmaceuticals & Drugs industry on the radar for traders and longer-horizon market watchers alike.

For readers tracking Gennex Laboratories Ltd. Stock News, the immediate story is straightforward: price action has strengthened sharply in a single session, the intraday range has been wide, and the move has come with 22,32,898 shares traded on BSE and turnover of Rs 2.61 crore. From a financial analysis perspective, the stock is also drawing attention because its valuation multiples, profitability metrics and sector positioning offer more context than price alone. In this Univest review, the focus is on what happened, what the numbers show, how the company compares with its industry benchmark and peers, and what investors may want to monitor next.

Gennex Laboratories Ltd. (GENNE) Share Price Today: Price Action Analysis

Gennex Laboratories Ltd. (GENNE) traded at Rs 11.7. versus the previous close of Rs 10.82, a rise of 8.13%. The stock opened at Rs 10.77, reached Rs 11.95, touched Rs 9.51. Reported volume was 22,32,898.

Gennex Laboratories Ltd. (GENNE) Fundamental Analysis

Gennex Laboratories Ltd. was valued at a P/E ratio of 13.55x, a P/B ratio of 1.16x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 10.71% and ROCE of 13.24%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 0.8, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Gennex Laboratories Ltd. Fundamental Analysis starts with scale and valuation. The company’s market capitalisation stands at Rs 262.87 crore, making it a micro cap within the Healthcare sector and the Pharmaceuticals & Drugs industry. On valuation, Gennex Laboratories Ltd. Share Price is trading at a P/E ratio of 13.55 and a P/B ratio of 1.16. These are important because they show how the market is pricing the business relative to earnings and book value. In simple terms, the P/E of 13.55 indicates how many times earnings investors are paying for, while the P/B of 1.16 places the stock only modestly above its accounting net worth.

Profitability metrics add another layer to the Gennex Laboratories Ltd. Stock Analysis. The company’s ROE is 10.71%, while ROCE is 13.24%. ROE measures returns generated on shareholder equity, and ROCE measures returns on capital employed. Both numbers are positive, which gives the stock a base level of operational relevance beyond short-term price action. The spread between ROE and ROCE is not extreme, suggesting that the current return profile is reasonably aligned across equity and capital employed.

EPS is Rs 0.8, meaning each share is backed by earnings of 80 paise on the supplied basis. That matters because it connects the market price to actual earnings power and helps explain the 13.55 P/E multiple. Dividend yield is 0, which tells investors that the current or historical payout relative to the present share price is nil in the supplied data. For readers focused on income, that means the present case for attention is linked more to stock performance and valuation than to dividend distribution.

Overall, the supplied fundamentals do add context to investor interest. Gennex Laboratories Ltd. Share Price is not being valued at the richer multiples seen in many pharmaceutical names, yet profitability remains positive. That makes the next logical step a comparison with the wider industry benchmark and listed peers, rather than a conclusion based only on today’s rally. Univest therefore turns to sector and peer data to understand where this stock sits inside its operating universe.

Sector and Industry Context

Gennex Laboratories Ltd. (GENNE) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Gennex Laboratories Ltd. (GENNE) has a P/E ratio of 13.55x, which is below the benchmark median of 26.47x, a difference of -48.81%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Gennex Laboratories Ltd. (GENNE) has a ROE of 10.71%, which is above the benchmark median of 9.91%, a difference of +8.07%. Gennex Laboratories Ltd. (GENNE) has a ROCE of 13.24%, which is above the benchmark median of 12.79%, a difference of +3.52%.

Track today’s top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

Gennex Laboratories Ltd. operates in Healthcare, specifically the Pharmaceuticals & Drugs industry, and the benchmark data gives a useful numerical frame for today’s move. Against 139 companies in the same industry benchmark, the company’s valuation and profitability profile looks mixed but clearly measurable, which is essential for a grounded market update.

The sector snapshot shows that the benchmark scope is the same industry, covering 139 companies. Within that universe, Gennex Laboratories Ltd. Share Price carries a company P/E of 13.55, versus an industry median P/E of 26.47 and an average of 40.28 across 105 companies with available P/E data. The benchmark P/E range runs from 2.98 to 361.02. On this comparison alone, the stock is trading below both the industry median and average on earnings multiple, which gives the price rise a more interesting backdrop than if it were already priced at the higher end of the pack.

The same pattern is visible on book value. The company’s P/B is 1.16, while the industry median is 1.77 and the average is 2.33 across 138 companies, with the benchmark range spanning from -21.33 to 27.19. That again places Gennex Laboratories Ltd. below the central tendency of its peer set on price-to-book.

Profitability is more balanced. The company’s ROE of 10.71% is above the industry median of 9.91% and above the average of 7.3%. ROCE at 13.24% is above the industry median of 12.79% but below the industry average of 14.83%. On size, the company’s market capitalisation of Rs 262.87 crore is above the benchmark median of Rs 137.8 crore but below the average of Rs 481.52 crore, with the industry range stretching from Rs 2.19 crore to Rs 2,985.15 crore. For Univest readers, that places the stock in the smaller half of the sector by size but not at the extreme bottom, while its valuation remains relatively restrained against benchmark multiples.

Peer Comparison

Gennex Laboratories Ltd. (GENNE) has a P/E ratio of 13.55x compared with the displayed peer median of 58.41x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 10.71% compares with a peer median of 11.42% across the companies shown in the table. ROCE stood at 13.24% versus the displayed peer median of 13.15%, providing a capital-efficiency comparison. Gennex Laboratories Ltd. (GENNE) has a market capitalisation of Rs 262.87 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Peer comparison shows where Gennex Laboratories Ltd. sits versus other listed Pharmaceuticals & Drugs names on market cap, valuation and return ratios. The supplied peer set is notably larger in market capitalisation, so the most useful comparison is relative efficiency and pricing rather than size alone.

At Rs 262.87 crore, Gennex Laboratories Ltd. is much smaller than the supplied peers, all of which range from Rs 2,139.2 crore to Rs 2,985.15 crore in market capitalisation. Dishman Carbogen Amcis Ltd. stands at Rs 2,985.15 crore, Beta Drugs Ltd. at Rs 2,827.67 crore, Hikal Ltd. at Rs 2,686.72 crore, Ind-Swift Laboratories Ltd. at Rs 2,645.37 crore and Fredun Pharmaceuticals Ltd. at Rs 2,559.68 crore. That gap is important because market-cap differences often influence liquidity, investor base and valuation consistency.

On P/E, Gennex Laboratories Ltd. at 13.55 is lower than Dishman Carbogen Amcis at 184.72, Beta Drugs at 68.16, Ind-Swift Laboratories at 46.15, Fredun Pharmaceuticals at 58.41, Sai Parenteral’s at 171, Venus Remedies at 20.56 and NGL Fine-Chem at 37.4. That makes Gennex one of the lower-priced names on earnings multiple among the supplied peers where P/E data is available.

Its P/B of 1.16 is above Dishman Carbogen Amcis at 0.45 but below Beta Drugs at 6.74, Hikal at 2.26, Ind-Swift Laboratories at 1.77, Fredun Pharmaceuticals at 8.73, Solara Active Pharma Sciences at 1.93, Sai Parenteral’s at 3.13, Panacea Biotec at 2.9, Venus Remedies at 3.48 and NGL Fine-Chem at 6.15.

Profitability is mixed but not weak. Gennex Laboratories Ltd. reports ROE of 10.71%, ahead of Dishman Carbogen Amcis at -2.89, Ind-Swift Laboratories at -0.78, Panacea Biotec at 0 and Venus Remedies at 9.85, while trailing Beta Drugs at 18.65, Hikal at 15.22, Fredun at 11.42, Solara at 17.23, Sai Parenteral’s at 13.9 and NGL Fine-Chem at 27.9. ROCE of 13.24% is above Dishman at -0.26, Ind-Swift at 8.31, Panacea at 5.36 and Venus Remedies at 7.89, and broadly in line with Fredun at 13.15 and Sai Parenteral’s at 12.97, though below Beta Drugs at 22.17 and NGL Fine-Chem at 33.91. For Univest, this suggests a stock that is smaller and more modestly valued than many peers, with profitability that sits in the middle rather than at either extreme.

Why Investors Are Watching Gennex Laboratories Ltd.

Investors are watching Gennex Laboratories Ltd. Share Price because today’s 8.13% move has pushed a micro cap pharmaceutical stock into the list of market movers, while the underlying valuation and profitability numbers give the move more analytical depth than a simple screen alert. In Stock Market Today and Share Market Today, that combination often drives attention.

• Verified price action: the stock rose Rs 0.88 to Rs 11.7 from a previous close of Rs 10.82.
• Intraday range: trade spanned from Rs 9.51 to Rs 11.95 after opening at Rs 10.77.
• Trading participation: 22,32,898 shares traded on BSE with turnover of Rs 2.61 crore.
• Fundamental context: P/E is 13.55, P/B is 1.16, ROE is 10.71% and ROCE is 13.24%.
• Sector positioning: valuation sits below industry median and average on both P/E and P/B.

What investors may monitor next is whether Gennex Laboratories Ltd. Share Price holds a meaningful part of today’s gain, how the stock behaves after touching Rs 11.95 intraday, and whether subsequent sessions continue to show active volume. Univest readers may also track whether the market continues to price the company below many pharmaceutical peers despite positive return ratios and a market capitalisation above the industry median.

About Gennex Laboratories Ltd.

Gennex Laboratories Ltd. is positioned within the Healthcare sector and operates in the Pharmaceuticals & Drugs industry. The supplied company context does not go beyond that sector and industry classification, but even this basic description helps frame the stock correctly for readers scanning Gennex Laboratories Ltd. Latest News and Gennex Laboratories Ltd. Company News.

As a Pharmaceuticals & Drugs company, Gennex Laboratories Ltd. belongs to an industry where investors commonly evaluate businesses through a combination of market capitalisation, earnings multiples, balance-sheet valuation and profitability ratios such as ROE and ROCE. In today’s case, the market is placing a Rs 262.87 crore valuation on the company, and the stock is being discussed not because of a broad corporate announcement in the supplied data, but because its share price has risen sharply enough in a single session to become a top gainer candidate.

The Healthcare and pharmaceuticals space also tends to attract close peer comparison because listed companies in the segment can trade at very different valuation ranges despite operating in the same broad industry bucket. That is relevant here because Gennex Laboratories Ltd. Share Price is currently valued below the benchmark median P/E and P/B for its industry, while still posting positive ROE and ROCE. For market participants, that makes the company worth tracking as a small listed pharma name whose stock performance is now drawing more attention in the Indian stock market.

Track Gennex Laboratories Ltd. Share Price on Univest

Use Gennex Laboratories Ltd. (GENNE) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Readers who want to follow Gennex Laboratories Ltd. Share Price more closely can use Univest to track live share price moves, market capitalisation, 52-week levels when available, valuation ratios, profitability metrics and broader market insights. Univest also helps users monitor Gennex Laboratories Ltd. Share Price Today alongside other Stocks Rising Today, making it easier to compare price action with fundamental analysis instead of relying only on headlines.

Because short-term market moves can be noisy, Univest is most useful when price data is viewed together with P/E, P/B, ROE, ROCE, EPS and peer comparison. That gives a more complete view of Gennex Laboratories Ltd. Stock Performance, especially in a micro cap name where daily volatility can be high and context matters as much as the headline move.

Frequently Asked Questions

Why is Gennex Laboratories Ltd. Share Price rising today?

Ans. Gennex Laboratories Ltd. Share Price rose because the stock gained 8.13% in today’s session, moving from Rs 10.82 to Rs 11.7. The supplied data confirms the price event and active trading, but it does not identify a company-specific catalyst.

What is Gennex Laboratories Ltd. Share Price Today?

Ans. Gennex Laboratories Ltd. Share Price Today is Rs 11.7. The stock was up Rs 0.88, or 8.13%, versus the previous close of Rs 10.82, making it one of the more notable micro cap gainers in today’s market update.

What were the day’s key trading levels for Gennex Laboratories Ltd.?

Ans. The stock opened at Rs 10.77, touched an intraday high of Rs 11.95 and a low of Rs 9.51, before trading at Rs 11.7. That wide range shows strong intraday volatility alongside a clearly positive closing position.

How much volume was traded in Gennex Laboratories Ltd. today?

Ans. Gennex Laboratories Ltd. recorded volume of 22,32,898 shares on BSE today, with turnover of Rs 2.61 crore. That level of activity suggests the 8.13% share price rise was supported by visible market participation rather than an isolated trade.

What is the market capitalisation of Gennex Laboratories Ltd.?

Ans. Gennex Laboratories Ltd. has a market capitalisation of Rs 262.87 crore. In the supplied classification, it falls in the Micro Cap category, which is why today’s price rise has drawn extra attention among smaller listed stocks.

Is Gennex Laboratories Ltd. expensive compared with its industry P/E?

Ans. On the supplied numbers, Gennex Laboratories Ltd. looks lower valued than its industry on earnings multiple. Its P/E is 13.55, versus the same-industry median of 26.47 and average of 40.28 across 105 companies with P/E data.

How does Gennex Laboratories Ltd. compare on price-to-book value?

Ans. The company’s P/B ratio is 1.16. That is below the industry median of 1.77 and below the industry average of 2.33 across 138 companies, indicating the stock is priced below the benchmark’s central valuation levels on book value.

What do ROE and ROCE show for Gennex Laboratories Ltd.?

Ans. Gennex Laboratories Ltd. reports ROE of 10.71% and ROCE of 13.24%. Those figures are above the industry median levels of 9.91% and 12.79%, respectively, although ROCE remains below the industry average of 14.83%.

What is the EPS and dividend yield of Gennex Laboratories Ltd.?

Ans. The supplied fundamentals show EPS of Rs 0.8 and dividend yield of 0 for Gennex Laboratories Ltd. That means the stock’s current market discussion is tied more to earnings valuation and price movement than to income payout.

Which sector and industry does Gennex Laboratories Ltd. belong to?

Ans. Gennex Laboratories Ltd. belongs to the Healthcare sector and the Pharmaceuticals & Drugs industry. Its sector benchmark covers 139 same-industry companies, which provides the basis for the valuation, profitability and peer comparisons used in this analysis.